Thousand Oaks, United States
Having been established over 25 years ago with financial backing from venture capital, Amgen is well aware of the difficulties encountered by fledgling biotech firms. For this reason, they introduced Amgen Ventures in 2004, their in-house venture capital fund. With an initial commitment of $100 million, this fund is designed to furnish nascent biotech enterprises with the means to pursue innovative breakthroughs with a particular emphasis on human therapeutics.
66
Total Investments
49
Portfolio Companies
-
Exits
4
Industries
General Information
Industries
Biotechnology, Health Care +2
Funding Stage
Series A +1
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Amgen Ventures
Recent Investments (66)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series A | •••••• | Apr 2024 | |
| Series D | •••••• | Feb 2024 | |
| Series B | •••••• | Dec 2023 | |
| Series A | •••••• | Nov 2023 | |
| Series B | •••••• | Sep 2023 | |
•••• ••••
|
Series B | •••••• | Jun 2023 |
|
•••• ••••
|
Series B | •••••• | Mar 2023 |
|
•••• ••••
|
Series C | •••••• | Nov 2022 |
|
•••• ••••
|
Series C | •••••• | Oct 2022 |
|
•••• ••••
|
Early VC | •••••• | Sep 2022 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
